MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.56
-0.30
-5.12%
Opening 13:56 02/26 EST
OPEN
5.84
PREV CLOSE
5.86
HIGH
5.95
LOW
5.44
VOLUME
123.02K
TURNOVER
--
52 WEEK HIGH
8.10
52 WEEK LOW
3.357
MARKET CAP
152.24M
P/E (TTM)
-2.4773
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks.com · 3d ago
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks.com · 4d ago
Uptrend Call Working As La Jolla Pharm Stock Rises 44.4% (LJPC)
Feb 12, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for La Jolla Pharm (NASDAQ:LJPC) on September 16th, 2020 at $4.75. In...
marketwatch.com · 02/12 05:26
La Jolla Pharm Up 59.4% Since SmarTrend Uptrend Call (LJPC)
SmarTrend identified an Uptrend for La Jolla Pharm (NASDAQ:LJPC) on September 16th, 2020 at $4.75. In approximately 5 months, La Jolla Pharm has returned 59.37% as of today's recent price of $7.57.
Comtex SmarTrend(R) · 02/04 18:01
La Jolla Pharm Has Returned 42.9% Since SmarTrend Recommendation (LJPC)
SmarTrend identified an Uptrend for La Jolla Pharm (NASDAQ:LJPC) on September 16th, 2020 at $4.75. In approximately 4 months, La Jolla Pharm has returned 42.95% as of today's recent price of $6.79.
Comtex SmarTrend(R) · 01/28 05:41
--Analyst Actions: Chardan Adjusts La Jolla Pharmaceutical's Price Target to $15 From $20, Keeps at Buy
MT Newswires · 01/25 08:58
Growth Investors: Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders will have a reason to smile today, with the analysts...
Simply Wall St. · 01/16 06:41
Growth Investors: Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
Simply Wall St. · 01/16 06:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LJPC. Analyze the recent business situations of La Jolla Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LJPC stock price target is 9.25 with a high estimate of 15.00 and a low estimate of 4.750.
EPS
Institutional Holdings
Institutions: 140
Institutional Holdings: 31.22M
% Owned: 114.03%
Shares Outstanding: 27.38M
TypeInstitutionsShares
Increased
19
717.95K
New
13
-67.87K
Decreased
20
685.63K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.24%
Pharmaceuticals & Medical Research
-0.77%
Key Executives
Chairman/Director
Kevin Tang
Chairman/Director
kevin Tang
President/Chief Executive Officer/Director
Larry Edwards
Chief Financial Officer/Chief Accounting Officer
Michael Hearne
Independent Director
Laura Douglass
Independent Director
Craig Johnson
Independent Director
David Ramsay
Independent Director
Robert Rosen
  • Dividends
  • Splits
  • Insider Activity
No Data
About LJPC
La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of intra-abdominal infections in patients 18 years of age and older. The LJPC-0118 (I.V. artesunate) is the Company’s investigational product for the treatment of malaria. The LJPC-401 (synthetic human hepcidin) is the Company’s investigational product for the treatment of conditions characterized by iron overload.

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LJPC stock methods without spending real money on the virtual paper trading platform.